A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder.
about
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)Pharmacotherapy of Attention-Deficit Hyperactivity Disorder in AdolescentsUsing Meta-analysis to Compare the Efficacy of Medications for Attention-Deficit/Hyperactivity Disorder in YouthsHypericum perforatum (St John's wort) for attention-deficit/hyperactivity disorder in children and adolescents: a randomized controlled trialComparing the efficacy of medications for ADHD using meta-analysisEfficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study dataComparing Auditory Noise Treatment with Stimulant Medication on Cognitive Task Performance in Children with Attention Deficit Hyperactivity Disorder: Results from a Pilot Study.Differences in Speech Recognition Between Children with Attention Deficits and Typically Developed Children Disappear When Exposed to 65 dB of Auditory Noise.Safety of stimulant treatment in attention deficit hyperactivity disorder: Part I.Safety of stimulant treatment in attention deficit hyperactivity disorder: part II.What influences clinicians' decisions about ADHD medication? Initial data from the Influences on Prescribing for ADHD Questionnaire (IPAQ).Treatment of attention deficit hyperactivity disorder with monoamine amino acid precursors and organic cation transporter assay interpretationThe effect of methylphenidate on neurofibromatosis type 1: a randomised, double-blind, placebo-controlled, crossover trial.Evaluation of risks associated with short- and long-term psychostimulant therapy for treatment of ADHD in children.An observational study of once-daily modified-release methylphenidate in ADHD: effectiveness on symptoms and impairment, and safety.Clinical use of a modified release methylphenidate in the treatment of childhood attention deficit hyperactivity disorder.Dose response effects of lisdexamfetamine dimesylate treatment in adults with ADHD: an exploratory studyPharmacotherapy for childhood obesity: present and future prospects.Sensitivity of scales to evaluate change in symptomatology with psychostimulants in different ADHD subtypes.Stimulant treatment in children with attention-deficit/hyperactivity disorder moderates adolescent academic outcomeEstimating the size of treatment effects: moving beyond p valuesChanges in emotions related to medication used to treat ADHD. Part I: literature review.Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder: a systematic literature review.Toward quality care in ADHD: defining the goals of treatment.Comparison of the pharmacokinetics and clinical efficacy of new extended-release formulations of methylphenidate.A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD).An evaluation of the pharmacokinetics of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder.Memantine versus Methylphenidate in Children and Adolescents with Attention Deficit Hyperactivity Disorder: A Double-Blind, Randomized Clinical Trial.Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison.An Evaluation on the Efficacy and Safety of Treatments for Attention Deficit Hyperactivity Disorder in Children and Adolescents: a Comparison of Multiple Treatments.The prototype/willingness model, academic versus health-risk information, and risk cognitions associated with nonmedical prescription stimulant use among college students.Does prior exposure to stimulants in children with ADHD impact cardiovascular parameters from lisdexamfetamine dimesylate?Forecasting three-month outcomes in a laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children With ADHD.ADHD in children: a path to free medicines.Meta-Analysis: Reduced Risk of Anxiety with Psychostimulant Treatment in Children with Attention-Deficit/Hyperactivity Disorder.[Attention deficit disorder and hyperactivity: does the treatment affect the statural growth?].Production of extended release mini-tablets using directly compressible grades of HPMC.New long-acting stimulants in children with ADHD.Individual change in methylphenidate use in a national sample of children aged 2 to 11 years.Efficacy and Tolerability of Different Interventions in Children and Adolescents with Attention Deficit Hyperactivity Disorder.
P2860
Q22061981-64757D84-43B6-4EF3-BF47-4302EA830C63Q22241419-26A39695-9B19-47BE-8E2E-9A552D72821DQ24642024-23337DD1-E10C-4C0D-9BF6-69A9D1451527Q24653919-852627E1-7AFB-4E76-A7B3-7E1D7A370622Q24685027-CB78DCA9-A23D-48F7-9300-456EA1B507F7Q24805432-1B7D5363-ABDE-4DCB-9130-3F8E9759043FQ30374187-27F81689-F771-409F-B2A9-938F35E56398Q30391541-7C69CE77-3439-47ED-80B3-FA217E74B21CQ30449130-1723D0BC-8659-47A1-89FF-E64F25342FC0Q30451303-47D7E7AB-60BF-4CD0-B615-5E865F04EF23Q30596479-A048D6BC-301E-4145-9E11-DFB9E76AC50DQ34025768-6439E462-63D4-4249-BE8E-E517307B4CBFQ34233624-7E18AE82-E866-46A1-9743-08FD52F2F26CQ34303865-6AD39E5F-E41B-4491-A7A5-6D622029D199Q35233563-8A901197-7369-4846-8DE5-DEAF184B662AQ35477867-447D4FC9-85FF-42AC-9261-CA924CF4C3B8Q35970045-805DA64A-C4FE-4C90-9C99-7CE22981A9ADQ36468087-11E3DE45-D8DC-4B4F-95A1-685C9BE2FF03Q36825927-5DEF2256-92A5-4DB3-B81C-0EA385B6B7C9Q37069181-CD52F97C-0BA0-4748-81FF-E9CDDD2A18FAQ37654952-D590FD13-2CE1-4358-B90B-24DD92613C10Q37793743-8D525421-7334-430E-A7B8-793C4BB079C0Q38019961-0A1A061F-5BE7-4699-B8D9-FAA1DA70ADDAQ38082894-D077BFE8-CA2F-4E13-9F62-BFF7EBAF3CD8Q38101134-5D8F13F3-BA3E-4D61-B8DC-A1B4406D6238Q38164670-E304EE3A-4E6C-440B-9506-D11BFBAB261BQ38214174-F01EACCB-9D23-4CF3-9D0F-D149522CADD5Q38401702-9E81FBFE-E5B5-4FA0-B115-AFBF10A6C05DQ38930427-F5B0F4D7-AA71-458E-80D6-760E3FBE752CQ39293219-4BEFFDE9-DA2E-4CB4-BC3E-0FA07A513B5FQ39546891-29AD8D5C-0B4C-4DE2-904B-E314EC24D282Q39834928-CF993FAB-652B-4271-800F-D293627C0E80Q40198244-E47B29E1-9D71-4659-9332-E17093205126Q41448511-779C8C57-AB2E-45E8-B073-AAB614E47FFCQ42170001-2442475E-356B-45F2-9390-70233228D7FEQ43045659-BC31C9DE-4BFE-45CB-8B90-64C4C50B4EEAQ44807396-3B82883D-FD95-49E8-9C8A-F916B2B14E51Q45293740-56ABE5EB-9F43-4556-A04B-5DF9E26F2853Q46438027-BE4DA70C-DF56-422B-A4E7-5BD888C81CADQ46584563-25A1D4E4-0F39-4732-B19A-2DB1DB3827DD
P2860
A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
A double-blind, placebo-contro ...... eficit/hyperactivity disorder.
@en
A double-blind, placebo-contro ...... eficit/hyperactivity disorder.
@nl
type
label
A double-blind, placebo-contro ...... eficit/hyperactivity disorder.
@en
A double-blind, placebo-contro ...... eficit/hyperactivity disorder.
@nl
prefLabel
A double-blind, placebo-contro ...... eficit/hyperactivity disorder.
@en
A double-blind, placebo-contro ...... eficit/hyperactivity disorder.
@nl
P2093
P356
P1433
P1476
A double-blind, placebo-contro ...... eficit/hyperactivity disorder.
@en
P2093
ADHD Study Group
James M Swanson
Laurence L Greenhill
Robert L Findling
P356
10.1542/PEDS.109.3.E39
P407
P577
2002-03-01T00:00:00Z